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PIEWPOINT
rug-Eluting Stents for Diabetes Mellitus
Rush to Judgment?
loke V. Finn, MD,* Igor F. Palacios, MD,* Adnan Kastrati, MD,† Herman K. Gold, MD*
oston, Massachusetts; and Munich, Germany
The two pivotal U.S. trials of drug-eluting stents do not establish the principle that these
stents are superior to thin-strut bare-metal stents for preventing repeat revascularization in
patients with diabetes. Neither study was adequately powered to make this determination.
Moreover, both studies used thick-strut stents known to have high restenosis rates as controls.
Low angiographic follow-up underestimates the true target lesion revascularization rate in the
Polymer-Based Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease (TAXUS-
IV) trial because of the high incidence of silent ischemia in patients with diabetes. Optimal
therapy for diabetic coronary disease should include a comprehensive approach directed
toward metabolic normalization in addition to local stent-based therapy. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.060Cardiol 2005;45:479–83) © 2005 by the American College of Cardiology Foundation
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vince the recent introduction of the Cypher (Cordis Corp.,
arren, New Jersey) and Taxus Express (Boston Scientific,
atick, Massachusetts) drug-eluting stents (DES) into the
.S. market, these devices are now considered by many to
e the standard of care for diabetic patients undergoing
oronary stent placement. However, careful examination of
he data from two pivotal U.S. trials, the Sirolimus-coated
X Velocity Balloon-Expandable Stent in the Treatment of
atients With De Novo Coronary Artery Lesions (SIRIUS)
rial and Polymer-Based Paclitaxel-Eluting Stent in Pa-
ients with Coronary Artery Disease (TAXUS-IV) trial,
emonstrate that this conclusion may not be supported by
he data generated by these studies (1,2).
ATIENT DEMOGRAPHICS AND STUDY DESIGN
iabetes mellitus was present in 26% of patients in the
IRIUS trial and in 32% of patients in the TAXUS-IV trial.
he trial designs were similar in that they excluded higher-
isk patients such as those with myocardial infarction, but
ere different in terms of requirement for angiographic
ollow-up. In the SIRIUS trial, approximately 67% of
atients with diabetes underwent angiographic follow-up at
40 days. As a result, most target lesion revascularization
TLR) was angiographically as well as clinically determined.
he design of TAXUS-IV trial was different in that the
ajority of diabetic patients in this trial (68%) did not
eceive angiographic follow-up. As a result, TLR rates in
his trial were mostly clinically driven (i.e., on the basis of
ymptoms). This is an important fact for two reasons: 1)
LR rates are often higher in trials with angiographic rather
From the *Cardiac Unit, Massachusetts General Hospital, Boston, Massachusetts;
nd †Deutsches Herzzentrum and 1. Med. Klinik rechts der Isar, Technische
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dge that they have sponsored research agreements through the Massachusetts
eneral Hospital with both Johnson & Johnson and Guidant Corporation. However,
his manuscript has not been underwritten by any corporation.0
Manuscript received July 25, 2004; revised manuscript received October 9, 2004,
ccepted October 18, 2004.han clinical follow-up and 2) clinical follow-up is notori-
usly unreliable in patients with diabetes because these
atients are known to have significantly greater incidence of
ilent ischemia than their non-diabetic counterparts (3,4).
n fact, TLR rates in this trial were approximately 50%
igher in patients receiving angiographic rather than clinical
ollow-up and could probably be expected to be much
igher within the diabetic subset (5). As a result of design
ifferences, comparison of results between these trials is
robably not possible.
Moreover, the importance of medical therapy to achieve
ecommended glycemic control targets and management of
sual risk factors in these patients cannot be overstated and
epresent important potential confounding factors in inter-
reting any data from these trials (6,7). No information
egarding the level of glycemic control of these patients as
ell as their medical regimen (e.g., number taking a statin)
as given, and medical regimens were simplified into
nsulin-requiring versus non–insulin-requiring. The validity
f subset analysis is uncertain given these uncontrolled-for
ariables.
In addition, neither trial was powered to determine
ifferences in restenosis among patients with diabetes, and
herefore any conclusions drawn carry a high risk that the
ifferences observed may be due to chance alone (type I
rror). Subset analysis is not a substitute for adequately
owered prospective randomized controlled studies in pa-
ients with type 2 diabetes undergoing coronary stent
lacement.
TUDY RESULTS
he SIRIUS trial. As for outcomes in the diabetic subset
f each trial, in SIRIUS, the overall nine-month rate of
ngiographic restenosis among diabetic patients enrolled in
he trial was 17.6% in the sirolimus-eluting stent (SES) arm
ersus 50.5% in the bare-metal stent (BMS) arm (p 
.001) (Table 1) (8). The 270-day TLR rates were 22.3% in
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Drug-Eluting Stents for Diabetes Mellitus February 15, 2005:479–83he BMS arm and 6.9% in the SES arm (p  0.001). The
70-day major adverse cardiac events evaluation revealed a
3% reduction in this end point among diabetic patients
reated with SES versus those receiving BMS (25% BMS vs.
.2% SES, p  0.001).
In non–insulin-requiring patients, the angiographic in-
egment restenosis rate was 12.3% in the SES arm and
0.7% in the BMS arm (p 0.001) (Table 2). Target lesion
evascularization was reduced in this group from 23.1% in
he BMS arm to 4.3% in the SES arm (p  0.001). The
verage reference vessel diameter (RVD) was 2.71 mm in
he BMS arm and 2.63 mm in the SES arm (p NS), with
n average lesion length of 15 mm in the BMS arm and 13
m in the SES arm (p  NS).
In insulin-requiring diabetic patients, the angiographic
n-segment restenosis rate at 270 days was 50% in the BMS
rm, which was not significantly different from 35% in the
ES arm (Table 2). Target lesion revascularization rates
ere also not significantly different between the two arms
20.5% BMS vs. 13.2% SES, p  NS). The baseline RVD
as 2.79 mm in the BMS arm and 2.77 mm in the SES arm
p  NS), with an average lesion length of 14.81 mm in the
MS arm and 14.5 mm in the SES arm (pNS). Multiple
ogistic regression analysis revealed diabetes mellitus to be a
ignificant predictor of TLR at 270 days (coefficient 0.5,
Abbreviations and Acronyms
BMS  bare-metal stent
DES  drug-eluting stents
ISAR-STEREO  Intracoronary Stenting and
Angiographic Results-Strut
Thickness Effect on Restenosis
Outcomes trial
PCI  percutaneous coronary intervention
PES  paclitaxel-eluting stent
PPAR  peroxisome proliferator-activated
receptor
RVD  reference vessel diameter
SES  sirolimus-eluting stent
SIRIUS  Sirolimus-coated BX Velocity
Balloon-Expandable Stent in the
Treatment of Patients With De
Novo Coronary Artery Lesions
TAXUS-IV  Polymer-Based Paclitaxel-Eluting
Stent in Patients with Coronary
Artery Disease
TLR  target lesion revascularization
Table 1. Diabetic Subset Analysis: SIRIUS (1)
SIRIUS
BMS SES
Angiographic restenosis 50.5%
n  101
17.6%
n  85
TLR 22.3%
n  148
6.9%
n  13
BMS  bare-metal stent; ISAR-STEREO  Intracoronary
stent; SIRIUS  Sirolimus-coated BX Velocity Balloon-Expand
Coronary Artery Lesions trial; Thin S  thin-strut stent; Thick Sdds ratio 1.65, p  0.03) in diabetic patients treated with
he Cypher stent.
he TAXUS-IV trial. The overall nine-month and one-
ear results from the TAXUS-IV trial have recently been
ublished (2,5). However, specific information on patients
ith diabetes, including percent of patients in each arm with
ngiographic follow-up and nine-month TLR rates, has not
et been published in peer-reviewed journals. Approxi-
ately 136 of 423 diabetic patients enrolled in the trial
nderwent follow-up angiography. This represents 32% of
he entire diabetic population enrolled in the trial. Mean
esion length was 14.4 mm in the paclitaxel-eluting stent
PES) arm and 14.4 mm in the BMS arm (p  NS). The
verage baseline RVD is not available. Nine-month angio-
raphic data from this subset of patients revealed the
ngiographic restenosis rate to be 29.7% in the BMS arm
nd 5.8 in the PES arm (p 0.003) among diabetic patients
reated with oral medications. Among diabetics treated with
nsulin, the angiographic restenosis rate was 42.9% in the
MS arm and 7.7% in the PES arm (p  0.007). One-year
VR rates for orally treated diabetics were 7.9% in the PES
rm and 21.6% in the BMS arm (p  0.005). For insulin-
reated patients, TVR was 6.2% in the PES arm and 19.4%
n the BMS arm (p  0.07), with the confidence interval
rossing beyond unity. It is interesting to note that the
2-month TVR rates for patients receiving the PES are
ctually lower in the insulin-treated population than in the
ral-treated diabetic group, an unexpected result that runs
ounter to all previously published data (9–11). Because of
ifferences in the design of this trial (i.e., number of patients
ith angiographic follow-up), it is unclear whether these
esults can be compared with those of the SIRIUS trial or
ther interventional trials involving coronary stent place-
ent in which the majority of patients underwent follow-up
ngiography.
he Intracoronary Stenting and Angiographic Results-
trut Thickness Effect on Restenosis Outcomes (ISAR-
TEREO) trial. In both the SIRIUS and TAXUS-IV trials,
he bare-metal control arm stents had very high restenosis rates
ikely related to the stent design, which overemphasized the
uperiority of drug delivery stents. The strut thickness of both
he BX Velocity (Cordis Corp., Johnson & Johnson, Warren,
ew Jersey) and the Express stent is significantly larger than
hat of the thin-strut stents such as the Multi-Link. Random-
zed trials have shown strut thickness to be an important
sus ISAR-STEREO (12,13)
ISAR-STEREO
p Value Thin S Thick S p Value
 0.001 19.7%
n  76
37.9%
n  95
0.01
 0.001 9.0%
n  122
21.9%
n  128
0.005
ng and Angiographic Results trial; SES  sirolimus-elutingVer
1
Stenti
able Stent in the Treatment of Patients With De Novo
 thick-strut stent; TLR  target lesion revascularization.
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February 15, 2005:479–83 Drug-Eluting Stents for Diabetes Mellituseterminant of angiographic restenosis and TLR in both
iabetic and non-diabetic patients. Data from two randomized
ontrolled clinical trials, the ISAR-STEREO and ISAR-
TEREO-2 trials, confirmed that reduced stent strut thick-
ess is associated with significantly improved angiographic and
linical restenosis rates (12,13). In these trials patients were
andomized to thin-strut (Multi-Link, Guidant Corp., Ad-
anced Cardiovascular Systems, Santa Clara, California) versus
hick-strut (Multi-Link Duet) (ISAR-STEREO trial) or BX
elocity (ISAR-STEREO-2 trial) stent implantation and
nderwent six-month follow-up angiography. Rates of angio-
raphic follow-up for diabetic patients in these trials were
pproximately 70%. Combined diabetic subset data from the
71 patients receiving angiographic follow-up in these trials
eveal six-month angiographic restenosis rates to be 37.9% in
igure 1. Comparison of rates of angiographic restenosis and target lesion
X Velocity Balloon-Expandable Stent in the treatment of Patients
Table 2. SIRIUS: Results From Insulin-Requi
Patients (8)
Non–Insulin-R
BMS
(n  104)
SES
(n  9
Angiographic restenosis* 50.7%
n  73
12.3%
n  6
TLR 23.1% 4.3%
MACE 26.0% 6.5%
*In segment.
MACE  major adverse cardiac events; TLR  target laclitaxel-Eluting Stent in Patients with Coronary Artery Disease (TAXUS-
TEREO) (12,13) trials (95% confidence intervals [CI] are illustrated).he thick-strut bare-metal arm (Duet or BX Velocity) and
9.7% (Multi-Link) in the thin-strut bare-metal arm (p 
.01). The six-month TLR in the 250 diabetic patients
ollowed was 21.9% in the thick-strut arm and 9% in the
hin-strut arm (p  0.005) (A. Kastrati, personal communi-
ation, April 13, 2004). In summary, the results using thin-
trut stents in diabetic patients in this trial compare favorably
ith those obtained with the SES in diabetic patients in the
IRIUS trial (Table 1).
ngiographic restenosis and TLR across the trials. Although
ata from the two pivotal U.S. trials using DES appear
mpressive at first glance, the confidence intervals for an-
iographic restenosis and TLR overlap when comparing the
ata from these trials with the data from the ISAR-
TEREO trial (Fig. 1). It remains unclear whether either
scularization (TLR) for diabetic patients enrolled in the Sirolimus-coated
De Novo Coronary Artery Lesions (SIRIUS) (1), Polymer-Based
Versus Non–Insulin-Requiring Diabetic
ng Insulin-Requiring
p Value
BMS
(n  44)
SES
(n  38) p Value
 0.001 50%
n  28
35%
n  20
0.38
 0.001 20.5% 13.2% 0.56
 0.001 22.7% 15.7% 0.58
evascularization; other abbreviations as in Table 1.reva
withring
equiri
3)
5IV) (2), and Intracoronary Stenting and Angiographic Results (ISAR-
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Drug-Eluting Stents for Diabetes Mellitus February 15, 2005:479–83ES commercially available in the U.S. randomized against
thin-strut stent of the Multi-Link design would show
ignificant benefit in patients with diabetes. Moreover, the
AXUS-IV study results for diabetic patients are not easily
omparable with the other two studies in which rates of
ollow-up angiography were much higher.
IABETES AND RISK OF
THEROSCLEROSIS PROGRESSION
lthough the goals of DES are to lower restenosis at the
tented site, the therapy is local and obviously will do
othing to prevent progression of coronary disease at other
ites. In addition to restenosis, non-culprit lesion progres-
ion is another important factor underlying adverse out-
omes seen in diabetic patients after percutaneous coronary
ntervention (PCI) (14). A large number of these patients
ndergo repeat PCI at a site different from that of the
nitially treated lesion (15). The Arterial Revascularization
herapies Study (ARTS) demonstrated a two-fold higher
ortality in diabetic patients with multi-vessel disease
ndergoing PCI versus coronary artery bypass surgery (16).
significant reason for this was non-culprit lesion progres-
ion. In the Prevention of Restenosis with Tranilast and its
utcomes (PRESTO) trial, which examined the effect of
ranilast on restenosis prevention after coronary stenting,
iabetic patients had a 33% increase over non-diabetic
atients in new lesion formation over the next nine months
17). Moreover, adverse clinical events, including myocar-
ial infarction and death, were more frequent in diabetic
ersus non-diabetic patients. In addition to its as-yet-
nproven benefit for diabetic patients in terms of lowering
estenosis, the long-term benefit of DES in these patients
ay be limited by their inability to retard non-culprit lesion
rogression. Newer systemic therapies that combat both
estenosis and progression of atherosclerosis are needed and
ay in the end be the best solution for patients with
iabetes.
FFECT OF DIABETES ON VASCULAR
IOLOGY: SYSTEMIC VERSUS LOCAL THERAPY
yperglycemia and insulin resistance are the two crucial
etabolic abnormalities defining type 2 diabetes mellitus
18). Together these pathophysiologic alterations drive both
therosclerosis and excessive neointimal formation after
oronary intervention. Any therapy based on the pathobi-
logy of this disease must target both of these processes.
eliance on local antiproliferative therapy using either
aclitaxel or sirolimus may treat local responses to stent-
nduced injury through prevention of smooth-muscle cell
roliferation, but they do not target the underlying systemic
erangements that affect the entire coronary circulation.
ew approaches using systemic therapies to target insulin
esistance, inflammatory signaling, endothelial dysfunction,
nd prothrombotic state are needed in order to significantly
mprove outcomes in this patient population. The glitazonesre agonists of the peroxisome proliferator-activated recep-
or (PPAR)-gamma, have multiple beneficial effects on
ascular cells, and are commercially available for the treat-
ent of type 2 diabetes (19). These drugs are known to: 1)
nhibit smooth-muscle cell growth and migration; 2) limit
he production of proinflammatory and proatherosclerotic
ytokines; 3) improve defects in fibrinolysis by decreasing
brinogen and plasminogen activator inhibitor-1 levels; and
) reduce insulin levels by improving insulin sensitivity in a
ariety of tissues (20,21). Haffner et al. (22) reported that in
atients with type 2 diabetes, treatment with 26 weeks of
he PPAR-gamma oral agonist rosiglitazone resulted in
ignificantly lower levels of C-reactive protein and matrix
etalloproteinase-9 compared with diabetic patients receiv-
ng placebo. These findings suggest a potential beneficial
ffect on overall atherosclerotic risk. Another group of
tudies by Minamikawa et al. (23) and Koshiyama et al. (24)
emonstrated that type 2 diabetic patients treated with
PAR-gamma agonists troglitazone or pioglitazone dem-
nstrated a significant decrease in common carotid intima-
o-media ratio compared with control patients, suggesting a
otent inhibitory effect on progression of early atheroscle-
osis.
tudy limitations. There are limitations to drawing con-
lusions from a non-randomized comparison because the
atient population and other demographic features (such as
he incidence of smoking and the severity of diabetes) may
iffer between trials. Definite conclusions can only be drawn
rom a prospective randomized trial in diabetic patients
omparing thin-strut BMS to DES.
onclusions. In summary, the two pivotal U.S. trials of
ES, the SIRIUS and TAXUS-IV trials, do not establish
he principle that DES are superior to well-designed thin-
trut BMS in terms of lowering repeat revascularization.
either study was adequately powered to determine differ-
nces within the diabetic subsets of these trials. Moreover,
oth trials compared DES to BMS with excessively high
estenosis rates, exaggerating any differences observed. The
mpressive angiographic results regarding restenosis rates
nd TLR in the diabetic subset of the TAXUS-IV trial are
n part related to the relatively low angiographic follow-up
ate. Finally, revascularization in diabetic patients utilizing
oronary stent implantation will also require systemic ther-
py to address alterations in underlying pathobiology re-
ponsible for both atherosclerosis progression and aggressive
eointimal formation.
eprint requests and correspondence: Dr. Aloke V. Finn,
assachusetts General Hospital, 55 Fruit Street, Boston, Massa-
husetts 02114. E-mail: afinn1@partners.org.
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